{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:28:32Z","timestamp":1793899712926,"version":"4.8.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"University of Bergen","id":[{"id":"https:\/\/ror.org\/03zga2b32","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s00415-026-14111-6","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:33:29Z","timestamp":1791362009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Healthcare costs and burden of myasthenia gravis for patients and society: a systematic review"],"prefix":"10.1007","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6522-5102","authenticated-orcid":false,"given":"Nils Erik","family":"Gilhus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selma Conradi","family":"Melsom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoffer","family":"Bugge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"14111_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16367","author":"G Antonini","year":"2023","unstructured":"Antonini G, Habetswallner F, Inghilleri M, Mantegazza R, Rodolico C, Sacc\u00e0 F, Sgarzi M, de Ruyck F, Paci S, Phillips G, Crippa L, Veronesi C, Perrone V, Degli Esposti L, Grp LHUS (2023) Real world study on prevalence, treatment and economic burden of myasthenia gravis in Italy. Heliyon. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16367","journal-title":"Heliyon"},{"key":"14111_CR2","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","volume":"22","author":"S Blum","year":"2015","unstructured":"Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164\u20131169","journal-title":"J Clin Neurosci"},{"issue":"1","key":"14111_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","volume":"13","author":"MI Boldingh","year":"2015","unstructured":"Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren J, Tallaksen CME (2015) An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Quality Life Outcomes 13(1):115","journal-title":"Health Quality Life Outcomes"},{"issue":"1","key":"14111_CR4","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00415-024-12768-5","volume":"272","author":"C Bugge","year":"2025","unstructured":"Bugge C, Engebretsen I, Kristiansen IS, Saether EM, Lindberg-Schager I, Arneberg F, Gilhus NE (2025) Medical costs of treating myasthenia gravis in patients who need intravenous immunoglobulin (IVIg) - a register-based study. J Neurol 272(1):15","journal-title":"J Neurol"},{"key":"14111_CR5","first-page":"460","volume":"58","author":"Q Cai","year":"2024","unstructured":"Cai Q, Batista AE, B\u00f6rsum J, Zhang QY, Isheden G, Kunovszki P, Gandhi K, Heerlein K, Brauner S (2024) Long-term healthcare resource utilization and costs among patients with myasthenia gravis: a Swedish nationwide population-based study. Neuroepidemiology 58:460\u2013469","journal-title":"Neuroepidemiology"},{"key":"14111_CR6","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00383-019-04486-1","volume":"35","author":"MA Catalano","year":"2019","unstructured":"Catalano MA, Mullan CW, Rich BS, Glick RD (2019) Pediatric thymectomy: a study of national trends in demographics, short-term outcomes, and cost. Pediatr Surg Int 35:749\u2013757","journal-title":"Pediatr Surg Int"},{"key":"14111_CR7","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3325\/cmj.2025.66.436","volume":"66","author":"F \u00c7ipi","year":"2025","unstructured":"\u00c7ipi F, Koloneci C, Marku A, Domi K, Tahiraj X, Malaj V, Hoxha M (2025) Health economic evaluations of myasthenia gravis: a systematic review. Croat Med J 66:436\u2013445","journal-title":"Croat Med J"},{"key":"14111_CR8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.pediatrneurol.2023.07.024","volume":"148","author":"C De Boer","year":"2023","unstructured":"De Boer C, Zeineddin S, Ott K, Hu AD, Linton S, George M, Rao VK, Abdullah F, Chin A, Goldstein SD (2023) Measuring the efficacy of thymectomy for pediatric myasthenia gravis across tertiary children\u2019s hospitals. Pediatr Neurol 148:17\u201322","journal-title":"Pediatr Neurol"},{"key":"14111_CR9","doi-asserted-by":"publisher","first-page":"1538789","DOI":"10.3389\/fpubh.2025.1538789","volume":"13","author":"S Dewilde","year":"2025","unstructured":"Dewilde S, Qi CZ, De Ruyck F, Paci S, van de Veire L, Griffiths A, Wolfe GI, Mantegazza R, Phillips G (2025) A cost analysis of reductions in work productivity for MG patients and their caregivers by symptom severity. Frontiers Pub Health 13:1538789","journal-title":"Frontiers Pub Health"},{"issue":"5","key":"14111_CR10","doi-asserted-by":"publisher","first-page":"e16233","DOI":"10.1111\/ene.16233","volume":"31","author":"I Engebretsen","year":"2024","unstructured":"Engebretsen I, Gilhus NE, Kristiansen IS, Saether EM, Lindberg-Schager I, Arneberg F, Bugge C (2024) The epidemiology and societal costs of myasthenia gravis in Norway: A non-interventional study using national registry data. European J Neurol 31(5):e16233","journal-title":"European J Neurol"},{"issue":"1","key":"14111_CR11","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1186\/s12883-016-0757-2","volume":"16","author":"A Frost","year":"2016","unstructured":"Frost A, Svendsen ML, Rahbek J, Stapelfeldt CM, Nielsen CV, Lund T (2016) Labour market participation and sick leave among patients diagnosed with myasthenia gravis in Denmark 1997\u20132011: a Danish nationwide cohort study. Bmc Neurol 16(1):224","journal-title":"Bmc Neurol"},{"key":"14111_CR12","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/mus.24960","volume":"53","author":"JC Furlan","year":"2016","unstructured":"Furlan JC, Barth D, Barnett C, Bril V (2016) Cost-minimization analysis comparing intravenous immunoglobulin with plasma exchange in the management of patients with myasthenia gravis. Muscle Nerve 53:872\u2013876","journal-title":"Muscle Nerve"},{"key":"14111_CR13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/bs.irn.2025.04.028","volume":"182","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, A B (2025) Epidemiology of myasthenia gravis. Int Rev Neurobiol 182:161\u2013196","journal-title":"Int Rev Neurobiol"},{"key":"14111_CR14","doi-asserted-by":"publisher","first-page":"2570","DOI":"10.1056\/NEJMra1602678","volume":"375","author":"NE Gilhus","year":"2016","unstructured":"Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570\u20132581","journal-title":"N Engl J Med"},{"key":"14111_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ene.70534","volume":"33","author":"NE Gilhus","year":"2026","unstructured":"Gilhus NE (2026) Myasthenia gravis with acetylcholine receptor antibodies in the very old: treatment challenges and diagnostic pitfalls. Eur J Neurol 33:e70534","journal-title":"Eur J Neurol"},{"issue":"5","key":"14111_CR16","doi-asserted-by":"publisher","first-page":"e16229","DOI":"10.1111\/ene.16229","volume":"31","author":"NE Gilhus","year":"2024","unstructured":"Gilhus NE, Andersen H, Andersen LK, Boldingh M, Laakso S, Leopoldsdottir MO, Madsen S, Piehl F, Popperud TH, Punga AR, Schirakow L, Vissing J (2024) Generalized myasthenia gravis with acetylcholine receptor antibodies A guidance for treatment. Eur J Neurol 31(5):e16229","journal-title":"Eur J Neurol"},{"key":"14111_CR17","first-page":"161","volume-title":"International review of neurobiology","author":"NE Gilhus","year":"2025","unstructured":"Gilhus NE, Breiner A (2025) Chapter eight - epidemiology of myasthenia gravis. In: Punga AR, Barnett-Tapia C (eds) International review of neurobiology. Academic Press, pp 161\u2013196"},{"key":"14111_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1111\/ene.12599","volume":"22","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17\u201323","journal-title":"Eur J Neurol"},{"key":"14111_CR19","doi-asserted-by":"crossref","unstructured":"NE. Gilhus, S. Tzartos, A. Evoli, J. Palaces, TM. Burns, J. Verschuuren 2019 Myasthenia gravis Nat Rev Disease Primers 5","DOI":"10.1038\/s41572-019-0079-y"},{"key":"14111_CR20","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/S1474-4422(15)00145-3","volume":"14","author":"NE Gilhus","year":"2015","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023\u20131036","journal-title":"Lancet Neurol"},{"issue":"21","key":"14111_CR21","first-page":"00583","volume":"50960\u20138966","author":"NEVJ Gilhus","year":"2021","unstructured":"Gilhus NEVJ, Hovland SIB, Simmonds H, Groot F, Palace J (2021) Myasthenia gravis: do not forget the patient perspective. J Neuromuscul Disord 50960\u20138966(21):00583\u201300586","journal-title":"J Neuromuscul Disord"},{"key":"14111_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1159\/000506310","volume":"54","author":"E Guastafierro","year":"2020","unstructured":"Guastafierro E, Tramacere I, Toppo C, Leonardi M, Mantegazza R, Bonanno S, Frangiamore R, Raggi A (2020) Employment in myasthenia gravis: a systematic literature review and meta-analysis. Neuroepidemiology 54:304\u2013312","journal-title":"Neuroepidemiology"},{"key":"14111_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1002\/mus.22212","volume":"44","author":"JT Guptill","year":"2011","unstructured":"Guptill JT, Marano A, Krueger A, Sanders DB (2011) Cost analysis of myasthenia gravis from a large U.S. insurance database. Muscle Nerve 44:907\u2013911","journal-title":"Muscle Nerve"},{"key":"14111_CR24","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/mus.26694","volume":"60","author":"L Harris","year":"2019","unstructured":"Harris L, Aban IB, Xin HC, Cutter G (2019) Employment in refractory myasthenia gravis: a Myasthenia Gravis Foundation of America Registry analysis. Muscle Nerve 60:700\u2013706","journal-title":"Muscle Nerve"},{"key":"14111_CR25","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1080\/13696998.2019.1592180","volume":"22","author":"L Harris","year":"2019","unstructured":"Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S (2019) Healthcare resource utilization by patients with treatment-refractory myasthenia gravis in England. J Med Econ 22:691\u2013697","journal-title":"J Med Econ"},{"issue":"10513","key":"14111_CR26","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1016\/S0140-6736(25)01637-X","volume":"406","author":"SI Hay","year":"2025","unstructured":"Hay SI, Ong KL, Santomauro DF et al (2025) Lancet 406(10513):1873\u20131922","journal-title":"Lancet"},{"issue":"12","key":"14111_CR27","doi-asserted-by":"publisher","first-page":"e214428","DOI":"10.1212\/WNL.0000000000214428","volume":"105","author":"XY Huang","year":"2025","unstructured":"Huang XY, Yu ZH, Cui Y, Zhang H, Fu M, Zhao YS, Liu P, Fan ML, Wu T, Zhang C, Qi GY, Shi FD (2025) Outcomes in relation to the age at onset in patients with myasthenia gravis. Neurology 105(12):e214428","journal-title":"Neurology"},{"key":"14111_CR28","doi-asserted-by":"publisher","first-page":"1247931","DOI":"10.3389\/fpubh.2023.1247931","volume":"11","author":"T Hughes","year":"2023","unstructured":"Hughes T, Howard JF Jr, Silvestri NJ, Anderson AEL, Sato M, Suchotliff S, Guptill JT, Phillips G (2023) The economic burden of individuals living with generalized myasthenia gravis and facing social determinants of health challenges. Frontiers Pub Health 11:1247931","journal-title":"Frontiers Pub Health"},{"key":"14111_CR29","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1080\/03007995.2025.2576597","volume":"41","author":"L Jackson","year":"2025","unstructured":"Jackson L, Liu ZW, Pesa J, Campbell AK, Choudhry Z, Batista AE, Souayah N (2025) Exacerbation and myasthenic crisis in generalized myasthenia gravis: real-world healthcare resource utilization and cost burden in the United States. Curr Med Res Opin 41:1735\u20131751","journal-title":"Curr Med Res Opin"},{"key":"14111_CR30","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1136\/pn-2025-004655","volume":"25","author":"S Jacob","year":"2025","unstructured":"Jacob S, Farrugia ME, Hewamadduma C, Norwood F, Hill M, Leite MI, McConville JP, Pinto AA, Spillane J, Sussman J, Viegas S (2025) Association of British Neurologists (ABN) autoimmune myasthenia gravis management guidelines (2025 update). Pract Neurol 25:422\u2013437","journal-title":"Pract Neurol"},{"issue":"4","key":"14111_CR31","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1159\/000548274","volume":"60","author":"SS Jing","year":"2025","unstructured":"Jing SS, Zhang ZH, Zhou YC, Zheng W, Fan R, Que WJ, Liu LQ, Lu D, Liu SY, Gan YQ, Xiao F (2025) Predictors of quality of life in myasthenia gravis patients from southwestern china: validation of clinical and socioenvironmental determinants. Neuroepidemiology 60(4):672\u2013682","journal-title":"Neuroepidemiology"},{"issue":"1","key":"14111_CR32","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1186\/s13023-025-03796-z","volume":"20","author":"B Johnson","year":"2025","unstructured":"Johnson B, Gibson G, Baskerville D, Castellano G, de Courcy J, Iqbal H, Piercy J, Williams A, Pinedo-Villanueva R, Rylands A (2025) Health-related quality of life and productivity burden for non-professional caregivers of adults with rare diseases: a real-world study. Orphanet J Rare Diseases 20(1):282","journal-title":"Orphanet J Rare Diseases"},{"key":"14111_CR33","doi-asserted-by":"publisher","first-page":"1586031","DOI":"10.3389\/fneur.2025.1586031","volume":"16","author":"M Khateb","year":"2025","unstructured":"Khateb M, Shelly S (2025) Mortality risk in patients with myasthenia gravis. Frontiers Neurol 16:1586031","journal-title":"Frontiers Neurol"},{"key":"14111_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40273-020-00912-8","volume":"38","author":"E Landfeldt","year":"2020","unstructured":"Landfeldt E, Pogoryelova O, Sejersen T, Zethraeus N, Breiner A, Lochmuller H (2020) Economic costs of myasthenia gravis: a systematic review. Pharmacoeconomics 38:715\u2013728","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"14111_CR35","doi-asserted-by":"publisher","first-page":"6687","DOI":"10.1038\/s41598-025-91372-7","volume":"15","author":"S Lehnerer","year":"2025","unstructured":"Lehnerer S, Herdick M, Mevius A, Grittner U, Gansel P, Joeres L, Biskup J, Meisel A (2025) The economic burden of Myasthenia gravis from the patients perspective and reflected in German claims data. Sci Rep 15(1):6687","journal-title":"Sci Rep"},{"key":"14111_CR36","doi-asserted-by":"publisher","first-page":"3050","DOI":"10.1007\/s00415-021-10891-1","volume":"269","author":"S Lehnerer","year":"2022","unstructured":"Lehnerer S, Jacobi J, Schilling R, Grittner U, Marbin D, Gerischer L, Stascheit F, Krause M, Hoffmann S, Meisel A (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol 269:3050\u20133063","journal-title":"J Neurol"},{"key":"14111_CR37","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1002\/mus.70045","volume":"73","author":"YB Li","year":"2026","unstructured":"Li YB, Bruckman D, Schold JD, Claytor B, Silvestri N, Hehir MK, Lee I (2026) Survival outcomes of Medicare-covered elderly US population with myasthenia gravis. Muscle Nerve 73:41\u201349","journal-title":"Muscle Nerve"},{"key":"14111_CR38","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/ana.22139","volume":"68","author":"A Mandawat","year":"2010","unstructured":"Mandawat A, Kaminski HJ, Cutter G, Katirji B, Alshekhlee A (2010) Comparative analysis of therapeutic options used for myasthenia gravis. Ann Neurol 68:797\u2013805","journal-title":"Ann Neurol"},{"issue":"1","key":"14111_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s12883-024-03553-y","volume":"24","author":"J McCallion","year":"2024","unstructured":"McCallion J, Borsi A, Noel W, Lee J, Karmous W, Sattler S, Boggia GM, Hardy EJ, Mitchell CR, Mitchell SA, Gilhus NE (2024) Systematic review of the patient burden of generalised myasthenia gravis in Europe, the Middle East, and Africa. Bmc Neurol 24(1):61","journal-title":"Bmc Neurol"},{"key":"14111_CR40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2026.125740","author":"N McLaren","year":"2026","unstructured":"McLaren N, Gutierrez AZ, Joo D, Roy B, Park M, Nowak RJ (2026) Variations in clinical features and disease burden of myasthenia gravis between racial and ethnic groups: a retrospective cohort study of two national databases. J Neurol Sci. https:\/\/doi.org\/10.1016\/j.jns.2026.125740","journal-title":"J Neurol Sci"},{"key":"14111_CR41","doi-asserted-by":"publisher","first-page":"E1617","DOI":"10.1212\/WNL.0000000000010574","volume":"95","author":"M Mendoza","year":"2020","unstructured":"Mendoza M, Tran C, Bril V, Katzberg HD, Barnett C (2020) Patient-acceptable symptom states in myasthenia gravis. Neurology 95:E1617\u2013E1628","journal-title":"Neurology"},{"key":"14111_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013278","volume":"7","author":"Y Nagane","year":"2017","unstructured":"Nagane Y, Murai H, Imai T, Yamamoto D, Tsuda E, Minami N, Suzuki Y, Kanai T, Uzawa A, Kawaguchi N, Masuda M, Konno S, Suzuki H, Aoki M, Utsugisawa K (2017) Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study. BMJ Open 7:e013278","journal-title":"BMJ Open"},{"key":"14111_CR43","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","volume":"96","author":"P Narayanaswami","year":"2021","unstructured":"Narayanaswami P, Sanders DB, Wolfe G, Benatar M, Cea G, Evoli A, Gilhus NE, Illa I, Kuntz NL, Massey J, Melms A, Murai H, Nicolle M, Palace J, Richman D, Verschuuren J (2021) International consensus guidance for management of myasthenia gravis 2020 update. Neurology 96:114\u2013122","journal-title":"Neurology"},{"issue":"1","key":"14111_CR44","doi-asserted-by":"publisher","first-page":"e210139","DOI":"10.1212\/WNL.0000000000210139","volume":"104","author":"JJJ Nielsen","year":"2025","unstructured":"Nielsen JJJ, Levison L, Andersen H (2025) Changes in myasthenia gravis incidence in denmark from 1985 to 2021 a nationwide population-based study. Neurology 104(1):e210139","journal-title":"Neurology"},{"issue":"12","key":"14111_CR45","doi-asserted-by":"publisher","first-page":"e213745","DOI":"10.1212\/WNL.0000000000213745","volume":"104","author":"JJJ Nielsen","year":"2025","unstructured":"Nielsen JJJ, Levison L, Andersen H (2025) Mortality in myasthenia gravis in denmark from 1985 to 2020: a population-based cohort study. Neurology 104(12):e213745","journal-title":"Neurology"},{"key":"14111_CR46","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1002\/mus.25624","volume":"56","author":"JO Omorodion","year":"2017","unstructured":"Omorodion JO, Pines JM, Kaminski HJ (2017) Inpatient cost analysis for treatment of myasthenia gravis. Muscle Nerve 56:1114\u20131118","journal-title":"Muscle Nerve"},{"key":"14111_CR47","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n160","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, Chou R, Glanville J, Grimshaw JM, Hr\u00f3bjartsson A, Lalu MM, Li T, Loder EW, Mayo-Wilson E, McDonald S, McGuinness LA, Stewart LA, Thomas J, Tricco AC, Welch VA, Whiting P, McKenzie JE (2021) PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ 372:n160","journal-title":"BMJ"},{"key":"14111_CR48","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1002\/mus.27992","volume":"69","author":"A Parthan","year":"2024","unstructured":"Parthan A, Royston M, Thanataveerat A, East EL, Parzynski CS, Habib AA (2024) Burden of illness and costs in patients with myasthenia gravis currently receiving treatment in the United States. Muscle Nerve 69:157\u2013165","journal-title":"Muscle Nerve"},{"issue":"12","key":"14111_CR49","doi-asserted-by":"publisher","first-page":"e16511","DOI":"10.1111\/ene.16511","volume":"31","author":"F Piehl","year":"2024","unstructured":"Piehl F, Vissing J, Mehtaelae J, Berggren F, Lindberg-Schager I, Pitsi D, Tsitlakidis E, Vesikansa A, Vaeaenaenen RM, Ylisaukko-oja T, Atula S (2024) Economic and societal burden of myasthenia gravis in Denmark, Finland, and Sweden: A population-based registry study. European J Neurol 31(12):e16511","journal-title":"European J Neurol"},{"key":"14111_CR50","doi-asserted-by":"publisher","first-page":"1448803","DOI":"10.3389\/fpubh.2025.1448803","volume":"13","author":"CY Qi","year":"2025","unstructured":"Qi CY, Narayanaswami P, Anderson AEL, Gelinas D, Li YB, Guptill JT, Amirthaganesan D, Ward C, Panchal R, Goyal A, Phillips G (2025) Racial disparities in acute care utilization among individuals with myasthenia gravis. Frontiers Pub Health 13:1448803","journal-title":"Frontiers Pub Health"},{"key":"14111_CR51","doi-asserted-by":"publisher","first-page":"175628642110654","DOI":"10.1177\/17562864211065406","volume":"14","author":"C Schneider-Gold","year":"2021","unstructured":"Schneider-Gold C, Gilhus NE (2021) Advances and challenges in the treatment of myasthenia gravis. Therapeutic Advances Neurol Disorders 14:17562864211065406","journal-title":"Therapeutic Advances Neurol Disorders"},{"key":"14111_CR52","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N, Ruck T (2019) Understanding the burden of refractory myasthenia gravis. Therapeutic Advances Neurol Disorders 12:1756286419832242","journal-title":"Therapeutic Advances Neurol Disorders"},{"key":"14111_CR53","doi-asserted-by":"publisher","first-page":"4130","DOI":"10.1016\/j.ymthe.2025.06.029","volume":"33","author":"S Schreiber","year":"2025","unstructured":"Schreiber S, Al-Dubai M, Vielhaber S, Lefterova L, Dietrich S, Ruck T, Meuth S, Walther D, Mougiakakos D (2025) Effective use of BCMA-targeting bispecific T cell-engaging antibody in treatment-refractory LRP4+myasthenia gravis. Mol Ther 33:4130\u20134134","journal-title":"Mol Ther"},{"key":"14111_CR54","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1159\/000539577","volume":"59","author":"F Sciancalepore","year":"2024","unstructured":"Sciancalepore F, Lombardi N, Valdiserra G, Bonaso M, Cappello E, Hyeraci G, Crescioli G, Celani MG, Cantisani TA, Brunori P, Vecchi S, Bacigalupo I, Locuratolo N, Lacorte E, Vanacore N, Kirchmayer U (2024) Prevalence, incidence, and mortality of myasthenia gravis and myasthenic syndromes: a systematic review. Neuroepidemiology 59:579\u2013592","journal-title":"Neuroepidemiology"},{"key":"14111_CR55","doi-asserted-by":"publisher","first-page":"1216595","DOI":"10.3389\/fneur.2023.1216595","volume":"14","author":"SP Shen","year":"2023","unstructured":"Shen SP, Herr KJ, Liu YF, Yang CC, Tang CH (2023) Healthcare resource utilization and costs associated with generalized myasthenia gravis: a retrospective matched cohort study using the National Health Insurance Research Database in Taiwan. Frontiers Neurol 14:1216595","journal-title":"Frontiers Neurol"},{"key":"14111_CR56","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.jocn.2016.11.003","volume":"38","author":"KK Sonkar","year":"2017","unstructured":"Sonkar KK, Bhoi SK, Dubey D, Kalita J, Misra UK (2017) Direct and indirect cost of myasthenia gravis: a prospective study from a tertiary care teaching hospital in India. J Clin Neurosci 38:114\u2013117","journal-title":"J Clin Neurosci"},{"key":"14111_CR57","doi-asserted-by":"publisher","first-page":"175628642412374","DOI":"10.1177\/17562864241237495","volume":"17","author":"J van Enkhuizen","year":"2024","unstructured":"van Enkhuizen J, Binns J, Betts A, Hosnijeh FS, Alexander M, McCormack M, Jacob S (2024) A retrospective observational study on characteristics, treatment patterns, and healthcare resource use of patients with myasthenia gravis in England. Therapeutic Advances Neurol Disorders 17:17562864241237496","journal-title":"Therapeutic Advances Neurol Disorders"},{"key":"14111_CR58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10072-020-04528-w","volume":"42","author":"BK Vitturi","year":"2021","unstructured":"Vitturi BK, Kim AIH, Mitre LP, Pellegrinelli A, Valerio BCO (2021) Social, professional and neuropsychiatric outcomes in patients with myasthenia gravis. Neurol Sci 42:167\u2013173","journal-title":"Neurol Sci"},{"key":"14111_CR59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04171-y","author":"T Vu","year":"2026","unstructured":"Vu T, Durmus H, Rivner M, Shroff S, Ragole T, Myers B, Pasnoor M, Small G, Karam C, Vullaganti M, Peltier A, Sahagian G, Feinberg MH, Slanksy A, Barnett-Tapia C, Siddiqi Z, Gwathmey K, Badruddoja MA, Kamboh H, Ruggerie RN, Fedak RR, Stewart CA, Kurtoglu M, Kalayoglu M, Singer M, Jewell CM, Miljkovic MD, Dimachkie M, Mozaffar T, Howard JF Jr., Team MGS (2026) BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. https:\/\/doi.org\/10.1038\/s41591-025-04171-y","journal-title":"Nat Med"},{"key":"14111_CR60","doi-asserted-by":"publisher","first-page":"175628642312132","DOI":"10.1177\/17562864231213240","volume":"16","author":"H Wiendl","year":"2023","unstructured":"Wiendl H, Abicht A, Chan AD, Della Marina A, Hagenacker T, Hekmat K, Hoffmann S, Hoffmann HS, Jander S, Keller C, Marx A, Melms A, Melzer N, M\u00fcller-Felber W, Pawlitzki M, R\u00fcckert JC, Schneider-Gold C, Schoser B, Schreiner B, Schroeter M, Schubert B, Sieb JP, Zimprich F, Meisel A (2023) Guideline for the management of myasthenic syndromes. Therapeutic Advances Neurol Disorders 16:17562864231213240","journal-title":"Therapeutic Advances Neurol Disorders"},{"key":"14111_CR61","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3346\/jkms.2025.40.e240","volume":"40","author":"J Woo","year":"2025","unstructured":"Woo J, Kim SW, Kim JH, Yuk J, Jung K, Cho Y, Park Y, Shin JY, Shin HY (2025) Identification of high-risk population for mortality and severe clinical outcomes among patients with myasthenia gravis: a nationwide population-based cohort study in korea. J Korean Med Sci 40:37","journal-title":"J Korean Med Sci"},{"key":"14111_CR62","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1080\/03007995.2025.2475075","volume":"41","author":"JZ Yu","year":"2025","unstructured":"Yu JZ, Zhang HY, Chen SQ, Dong D (2025) Economic burden of myasthenia gravis in China: a nationwide registry-based study. Curr Med Res Opin 41:487\u2013493","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14111-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14111-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-026-14111-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:05:16Z","timestamp":1793898316000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-026-14111-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["14111"],"URL":"https:\/\/doi.org\/10.1007\/s00415-026-14111-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"22 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.E. Gilhus has received honoraria or financial support from Alexion, Amgen, Argenx, Denka, Dianthus, Grifols, Huma, Janssen, Johnson & Johnson, Lundbeck, Merck, NMD Pharma, Novartis, Regeneron, Roche, Takeda, UCB. S.C. Melsom and C. Bugge are affiliated with Oslo Economics and have performed consultancy assignments for several private and public companies in recent years. Oslo Economics have not received any funding related to the work on this article.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Being a systematic literature review, no ethical approval or consent was necessary.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI-tools were used only for language improvement of drafted parts of the manuscript.","order":3,"name":"Ethics","label":"Declaration of AI-assisted technologies","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"648"}}